Cell Signaling Technology Logo
1% for the planet logo
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

IGFBP5 (E3H3Z) Rabbit mAb #76541

Filter:
  • WB
  • IF

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 32
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunofluorescence (Immunocytochemistry) 1:100 - 1:400

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #64746.

    Protocol

    Specificity / Sensitivity

    IGFBP5 (E3H3Z) Rabbit mAb recognizes endogenous levels of total IGFBP5 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to human IGFBP5 protein.

    Background

    Insulin-like growth factor (IGF) signaling plays a major role in regulating the proliferation and metabolism of normal and malignant cells. IGF-binding proteins (IGFBPs) play an integral role in modifying IGF actions in a wide variety of cell types. The six IGFBP family members share a high affinity for IGF binding and are structurally related, but are encoded by distinct genes (1). IGFBPs can exert stimulatory or inhibitory effects by controlling IGF availability through high affinity binding of IGF at the carboxy-terminal domain (2,3). IGFBP5 belongs to the high affinity IGF binding family. The effects of IGFBP5 on cancer development are either positive or negative depending on the cancer type (4). IGFBP5 has been shown to regulate tumor cell survival, apoptosis, migration, and metastasis by mechanism of IGF-dependent or IGF-independent actions (4-6). Downregulation of IGFBP5 is associated with therapeutic resistance in breast cancer and esophageal carcinoma. Meanwhile, upregulation of the protein can reverse drug resistance (7-9).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.